However, although α2A-ARs contributes the significantly inhibitory effect on NE release, other subtypes of α2-AR, such as α2B-AR and α2C-AR may have less effect on NE release, indicating that α2-adrenoceptors antagonists might be better drugs for the treatment of depression. Here, ADORA2A is linked to major depressive disorder.